Head & Neck

Head & Neck CT Perfusion: Predicting Who Responds

Fellowship-level neuroradiology teaching by E. Brooke Schrickel, MD. Open this topic in the interactive reading room →

Core clinical idea

CT perfusion is a noninvasive surrogate for tumor angiogenesis (microvascular density, potentially hypoxia); its clinically interesting use is predicting — early — which head and neck cancers will respond to non-surgical organ-preservation therapy, so non-responders reach salvage while salvage still works. This is an emerging research application, not a daily-read protocol.

Bottom line

CT perfusion is a noninvasive surrogate for tumor angiogenesis whose real value is predicting — early — who will respond to organ-preservation therapy, so non-responders reach salvage in time.

Core workstation questions

What is this perfusion map a surrogate for, and is blood volume/flow (the better-correlated parameters) driving the interpretation?
Is this being used to predict organ-preservation response, and at what point in treatment (pre-treatment vs mid-course)?
Are the cutoffs being applied validated, or study-specific numbers that shouldn't be treated as absolute?
If this looks like a non-responder, does that change the path toward early surgical salvage while it's still effective?

What changes reporting / management

Frame perfusion as a surrogate for angiogenesis/microvascular density, weighting blood volume and blood flow over transit time and permeability.
Pre-treatment blood volume may predict induction-chemo response (higher blood volume, higher likelihood of response).
Intra-treatment (mid-course) perfusion may flag non-responders early (drop in blood volume = responder; no change/rise = non-responder), enabling early salvage.
Treat predictive cutoffs as emerging/unvalidated, not routine clinical thresholds.

Practical traps

Memorizing study-specific cutoffs as validated daily-use thresholds.
Over-promising perfusion as a routine clinical tool when the evidence base is small/emerging.
Trusting mean transit time and capillary permeability as response surrogates when blood volume/flow are the better-correlated parameters.
Relying on the subjective >50% anatomic response threshold as if it were objective.

Teaching pearls

CT perfusion is a surrogate for microvascular density and tumor angiogenesis — and potentially hypoxia.
Blood volume and blood flow track with angiogenesis; transit time and permeability are weaker.
The payoff is timing: the first attempt is the best chance to cure, so flagging non-responders early matters.
Treat the predictive cutoffs as emerging research thresholds, not validated daily-use numbers.

Source lectures

CT Perfusion of the Head and Neck

Educational material for radiology residents and neuroradiology fellows. Nothing here drives individual patient care, and it contains no patient data.